Godavari Biorefineries Limited has reached near-complete utilization of its Rs. 325.00 crore Initial Public Offering proceeds, marking the conclusion of its IPO fund deployment as outlined in CARE Ratings Limited's final monitoring agency report for the quarter ended December 31, 2025.

IPO Proceeds Utilization Summary

The company has utilized Rs. 324.91 crore out of the total Rs. 325.00 crore IPO proceeds, leaving only Rs. 0.09 crore unutilized. This represents a utilization rate of 99.97% of the total funds raised through the public issue conducted from October 23, 2024 to October 25, 2024.

Fund Allocation Revisions

During Q3 FY26, the company implemented significant revisions to its fund allocation strategy through a board resolution dated May 24, 2025. The company reclassified Rs. 1.91 crore from surplus issue expenses to general corporate purposes during the quarter, adding to the previously reclassified Rs. 1.46 crore, bringing the total reclassification to Rs. 3.37 crore.

Quarterly Fund Deployment

During Q3 FY26, the company utilized Rs. 1.95 crore of IPO proceeds across different categories:

• Issue Expenses: Rs. 0.07 crore, including Rs. 0.02 crore for reimbursement of previously incurred expenses
• General Corporate Purposes: Rs. 1.88 crore primarily for vendor payments
• Debt Repayment: No utilization during the quarter as this component was completed in earlier periods

Financial Performance Challenges

The monitoring report highlights concerning financial performance trends. The company reported a net loss of Rs. 23.41 crore in FY25 compared to a net profit of Rs. 12.30 crore in FY24 on a consolidated basis. The losses continued in H1 FY26 with Rs. 57.61 crore in net losses.

The company's management clarified that FY25 losses included a one-time notional additional deferred tax liability of Rs. 24.00 crore due to changes in the Income Tax Act in July 2024, which removed indexation benefits for corporates. For H1 FY26, losses were attributed to the sugar division's off-season period, though results were reportedly better than H1 FY25.

Regulatory Compliance and Final Report

This marks the final monitoring agency report for the Rs. 325.00 crore initial public offering, as confirmed by CARE Ratings Limited. The report was prepared in compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 41 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The monitoring agency noted that while there was a minor deviation of Rs. 0.09 crore (0.03%) from the total proceeds transferred to the monitoring account, this fell within the acceptable range of up to 10% deviation. The company explained that merchant bankers serve as authorized signatories for transfers from the public issue account to the monitoring account, limiting the company's direct control over these transfers.

Godavari Biorefineries Limited announced its financial results for the quarter and nine months ended December 31, 2025, demonstrating strong operational performance driven by operating leverage and improved margins. The bio-based specialty chemicals pioneer reported total income of Rs. 461.9 crore for Q3FY26, marking a 2.5% year-on-year growth.

Strong Financial Performance in Q3FY26

The company delivered impressive profitability improvements across key metrics during the quarter. EBITDA grew 13.8% year-on-year to Rs. 45.1 crore, while PBT before exceptional items surged 152.2% to Rs. 21.4 crore, showcasing effective operational execution.

The company's margin expansion reflects its strategic focus on high-margin segments, with EBITDA margin improving to 9.8% from 8.8% in the previous year and PBT margin rising significantly to 4.6% from 1.9%.

Segment-wise Performance Analysis

The Bio-based Chemicals segment emerged as a key growth driver, with EBITDA increasing 76.7% year-on-year to Rs. 10.9 crore in Q3FY26. The Sugar & Cogeneration segment also performed well, recording EBITDA growth of 28.1% to Rs. 32.1 crore. However, the Ethanol segment faced challenges with EBITDA declining 56.6% to Rs. 4.2 crore.

The revenue mix remained consistent with the previous year, with Sugar & Cogeneration contributing 39%, Bio-Based Chemicals 31%, Ethanol 29%, and Unallocated segments 1% of the total revenue from operations of Rs. 460 crore.

Strategic Expansion and Capacity Enhancement

The investor presentation highlighted significant strategic initiatives, including the upcoming commissioning of a 200 KLPD fungible grain/maize distillery in Q1 FY27. This expansion will add 60 million litres of ethanol capacity per annum, enhancing operational flexibility and supporting India's Ethanol Blending Initiative through feedstock diversification.

Earnings Conference Call Recording Available

On February 19, 2026, the company uploaded the audio recording of its earnings conference call for Q3 and 9M FY26 on its website, complying with Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording is accessible at the company's official website for stakeholder reference.

Innovation and Sustainability Initiatives

The investor presentation emphasized the company's commitment to green chemistry and sustainable innovation. Key highlights include revolutionary CO2 conversion technology that transforms industrial emissions into Dimethyl Ether (DME), supporting climate change mitigation efforts. Additionally, the company's drug discovery division, Sathgen Therapeutics LLC, was incorporated in the United States as a wholly-owned step-down subsidiary to pursue licensing partnerships for anti-cancer drug development.

Regulatory Compliance and Governance

Following SEBI regulations, the company published its Q3FY26 unaudited financial results in Financial Express newspapers on February 15, 2026. Verma Mehta & Associates, Chartered Accountants, conducted a limited review of the company's unaudited consolidated and standalone financial results for Q3FY26 under Regulation 33, confirming compliance with Indian Accounting Standard 34 "Interim Financial Reporting."